reason report
bottom line view purchas otezla sensibl
expens although ftc argument difficult appreci
still dont understand otezla portfolio
phase ok portfolio enbrel
biosimilar humira indic ok analysi
impact affect confus
point view opinion net valu transact depend
revenu expect product assum
continu substanti commerci support product
remain patent life sale abl reduc
invest time mainten support sale
assum product patent life inde us
outsid us transact npv posit
achiev revenu higher current consensu
assum continu growth otezla patent life otezla
forecast ultim consensu mid-
basi forecast product gener posit npv
approxim per share use consensu forecast
similar assumpt profit npv rang
use forecast purchas break even cumul
cash basi wherea use consensu break-even year
includ otezla new model base
prior forecast otezla expect increment expens
associ product price target increas
like profil new addit inflammatori
diseas portfolio given price paid modest impact
compani overal valu pend realiz revenu perform
import issu remain amgen portfolio progress
view posit although key program still
rel earli develop rate market perform
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
disclosur regard financi impact otezla transact pay
otezla translat net cash price factor present
valu cash tax benefit period asset amort sg expens
 expens expect increas respect
approxim half increment spend support intern pipelin
particularli earlier-stag oncolog asset transact expect close late
guid toward otezla sale growth averag low double-digit rang loss
us patent protect patent expir potenti earlier
non-u geographi expect loss patent protect otezla us coincid
time enbrel us loe thu accentu revenu eros risk
although tax cash benefit realiz asset amort manag expect
increas compani non-gaap effect tax rate move forward deal
manag commentari suggest cash cash break-even manag
commentari impli cash break-even occur around halfway patent
expir even use materi higher revenu forecast assum oper
margin reach purchas break even cash basi use
consensu invest break even cash basi manag highlight
multipl opportun indic expans includ mild-to-moder scalp genit
psoriasi pso adult well moderate-to-sever pso juvenil idiopath arthriti
behcet pediatr patient
accret ep despit potenti neg valu creation consist manag
commentari expect otezla immedi accret pro forma earn
onward ep increas use consensu forecast similar
assumpt estim npv otezla lower
purchas price factor acquisit price cash tax benefit
calcul npv approxim use revenu estim
significantli higher consensu calcul npv net npv
approxim sensit analysi suggest otezla would need
achiev sale higher consensu order achiev posit npv exhibit
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock
sni rhhbi gsk nv celg price sale multipl larg cap
biotechnolog pharma compani novo nv celg
discount cash flow dcf use rel multipl larg cap biopharma
compani ep appli ep estim
give one year futur valu use establish larg cap futur revenu multipl
sale appli revenu forecast give futur
valu final dcf valuat base current outlook compani
exist product probability-weight revenu contribut late-stag pipelin
program discount compani wacc give fair valu today
averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
brand
type event
event trial detail
date known
up/down
leerink view
extend phase result nsclc
close otezla acquisit
phase candor trial combin
darzalex dexamethason
svb leerink llc research compani file
million
corp partner revenue incl royalti
po probabl success fda approv
sbv leerink llc research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
sbv leerink llc research compani file
analysi stock price svb leerink target
method model larg cap healthcar growth stock ep multipl ep
appli amgen ep
svb leerink updat ep estim
current averag ep multipl consensu ep compar
slow grow us eu larg cap biopharma stock
impli target price ep
celg revenu multipl appli svb leerink
svb leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma comp
method dcf adjust debt declin flow
stabl termin cash flow growth discount wacc
present valu flow termin valu
averag method
svb leerink llc research compani file factset
